• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles Benzothiazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzothiazoles

Riluzole Hydrochloride (CAS No. 850608-87-6): An Overview of Its Properties, Applications, and Recent Research

Riluzole hydrochloride (CAS No. 850608-87-6) is a pharmacologically active compound that has garnered significant attention in the field of neurology and neuropharmacology. This compound is a salt form of riluzole, a well-known drug used primarily in the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. The hydrochloride salt form enhances the solubility and stability of riluzole, making it more suitable for pharmaceutical applications.

The chemical structure of riluzole hydrochloride consists of a benzothiazole core with additional functional groups that contribute to its pharmacological properties. Specifically, the compound has a molecular formula of C12H14N4O2·HCl and a molecular weight of approximately 279.73 g/mol. The presence of the hydrochloride salt form ensures better absorption and bioavailability when administered orally.

In terms of its mechanism of action, riluzole hydrochloride primarily functions as a glutamate release inhibitor. Glutamate is an excitatory neurotransmitter that plays a crucial role in neuronal communication. However, excessive glutamate release can lead to excitotoxicity, which is implicated in various neurological disorders, including ALS. By inhibiting glutamate release, riluzole hydrochloride helps to reduce neuronal damage and slow the progression of ALS.

Recent research has also explored the potential of riluzole hydrochloride in other neurological conditions. For instance, studies have shown that it may have beneficial effects in treating spinal cord injuries and traumatic brain injuries by reducing secondary injury mechanisms such as inflammation and oxidative stress. Additionally, there is growing interest in its potential use as an adjunct therapy in psychiatric disorders such as depression and anxiety, where glutamate dysregulation is thought to play a role.

The clinical efficacy of riluzole hydrochloride has been well-documented in numerous trials. The most significant evidence comes from large-scale clinical studies in ALS patients, where it has been shown to modestly extend survival and improve quality of life. However, the exact therapeutic window and optimal dosing regimens are still subjects of ongoing research to maximize its benefits while minimizing side effects.

From a safety perspective, riluzole hydrochloride is generally well-tolerated, but like any medication, it can cause side effects. Common adverse effects include gastrointestinal disturbances such as nausea and vomiting, as well as liver function abnormalities. Regular monitoring of liver enzymes is recommended during treatment to ensure early detection and management of any hepatic issues.

In the pharmaceutical industry, the production and formulation of riluzole hydrochloride involve stringent quality control measures to ensure purity and consistency. Advanced manufacturing techniques are employed to achieve high yields and stability, making it suitable for long-term storage and distribution. The compound is typically supplied as a white to off-white crystalline powder and is formulated into various dosage forms such as tablets and oral solutions.

The future outlook for riluzole hydrochloride remains promising. Ongoing research aims to further elucidate its mechanisms of action and explore new therapeutic applications beyond ALS. Additionally, efforts are being made to develop novel delivery systems that can enhance its bioavailability and reduce side effects. These advancements could potentially expand the therapeutic utility of this compound and improve patient outcomes.

In conclusion, riluzole hydrochloride (CAS No. 850608-87-6) is a valuable compound with significant therapeutic potential in neurology and related fields. Its unique properties make it an important tool in the treatment of ALS and other neurological conditions. As research continues to advance, it is likely that new insights will emerge, further solidifying its position as a key player in modern pharmacotherapy.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)